Table. 1.

Comparison of clinical and laboratory parameters based on detectable de novo DSA

Variable Undetectablede novo DSA (n=14) Detectablede novo DSA (n=21) P-value
Recipient age at diagnosis (yr) 49.0±11.7 50.6±13.4 0.723
Recipient sex (male:female) 8 (57):6 (43) 16 (76):5 (24) 0.283
Donor age at diagnosis (yr) 44.1±11.7 43.5±14.6 0.907
Donor sex (male:female) 7 (50):7 (50) 10 (48):11 (52) 1.000
KDPI score (%) 53.5±23.3 82.3±17.7 0.208
Dialysis duration (mo) 41.6±48.9 35.6±44.1 0.706
Donor type (living:deceased) 9 (64):5 (36) 15 (71):6 (29) 0.721
Cause of end-stage renal disease 0.141
Glomerulonephritis 10 (72) 17 (81)
Hypertension 1 (7) 4 (19)
Diabetes mellitus 1 (7) 0
Polycystic kidney disease 2 (14) 0
HLA mismatch number 3.5±1.7 3.7±0.9 0.600
Preformed DSA 0 4 (19.0) 0.133
PRA >50% at diagnosis of CABMR 3 (21.4) 14 (66.7) 0.032
Class I DSA (A:B) at diagnosis of CABMR NA 3:3
Class II DSA (DR:DQ) at diagnosis of CABMR NA 11:7
Induction 0.532
Basiliximab 7 (50.0) 13 (61.9)
Antithymocyte globulin 1 (7.1) 3 (14.3)
None 6 (42.9) 5 (23.8)
Main immunosuppressant
Tacrolimus:cyclosporine
At KT 11 (78.6):3 (21.4) 18 (85.7):3 (14.3) 0.664
At diagnosis 12 (85.7):2 (14.3) 18 (85.7):3 (14.3) 1.000
After diagnosis or treatment 12 (85.7):2 (14.3) 17 (81.0):4 (19.0) 0.642
Previous BPAR 3 (21.4) 5 (23.8) 1.000
Coexistence of TCMR 1 (7.1) 1 (4.8) 1.000
Time from KT to development of de novo DSA (mo) NA 91.6±77.4
Time from KT to diagnosis of CABMR (mo) 101.6±59.6 90.3±72.9 0.634

Values are presented as mean±standard deviation or number (%).

DSA, donor-specific antibody; KDPI, kidney donor profile index; HLA, human leukocyte antigen; PRA, panel reactive antibody; CABMR, chronic antibody-mediated rejection; NA, not applicable; KT, kidney transplantation; BPAR, biopsy-proven acute rejection; TCMR, T-cell mediated rejection.

Korean J Transplant 2021;35:33~40 https://doi.org/10.4285/kjt.20.0052
© Korean Journal of Transplantation